PrEP is a new and efficacious HIV prevention method where HIV negative individuals take antiretrovirals to prevent infection. PrEP has been made available and is reimbursed for persons at high risk of HIV infection in Belgium since June 2017.
PrEP is relatively new and its reach, delivery and use need to be better understood to optimally serve communities, HIV prevention organisations and healthcare providers. Important questions on whether and how the demonstrated clinical efficacy of PrEP will translate into population-level effectiveness are still unanswered.
The overall objective of PROMISE is to learn how PrEP rollout can be optimised to result in maximum impact on HIV and sexual health.
PROMISE consists of 4 separate, interrelated work packages. Each package has its own specific research questions and research methods.